About
Explore Cell Therapies

About Cell Therapies

Our Facility

View our Services

Partnerships and Collaborations

Careers at Cell Therapies

Contact us

Since 2003, Cell Therapies has manufactured cell therapies, ex vivo gene therapies, and regenerative medicine products under GMP standards to meet global regulatory requirements.

Learn about Cell Therapies
Services
Explore Services

Contract Manufacturing

Technology Transfer

Process Development

Analytical Testing and Development

Quality as a Service

Consulting and Advisory

Clinical Trial Support

Cryopreservation & Logistics

Digitalisation & Automation

With over two decades of experience in GMP manufacturing of cell-based products, Cell Therapies is a trusted partner in transforming promising research into scalable, compliant, and commercially viable therapies.

Learn about Our Services
Facility
Careers
Explore Careers

Careers at Cell Therapies

View Current Opportunities

Upload your Resume

We are always on the lookout for curious minds, problem-solvers, and biotech enthusiasts to join our team. If you have a background in GMP manufacturing, QC, QA, engineering, or cell and gene therapy development, we would love to hear from you.

Find out about a career at Cell Therapies
News and Resources
Explore News and Resources

All News and Resources

News

Resources

Filter
All News
Resources

Cell Therapies Supports Commencement of Australian Phase I/Ib Clinical Trial of A-SEEDS’ ACS2015 CAR-T Therapy for Solid Tumours
Cell Therapies Supports Commencement of Australian Phase I/Ib Clinical Trial of A-SEEDS’ ACS2015 CAR-T Therapy for Solid Tumours
Read More

Translating innovative cell therapies: What is GMP?
Translating innovative cell therapies: What is GMP?
Read More

Cell Therapies and Skin2Neuron Announce Manufacturing Agreement to Advance First in Human Neurorestorative Cell Therapy
Cell Therapies and Skin2Neuron Announce Manufacturing Agreement to Advance First in Human Neurorestorative Cell Therapy
Read More

Read the latest from Cell Therapies
Contact

News

Cell Therapies Supports Commencement of Australian Phase I/Ib Clinical Trial of A-SEEDS’ ACS2015 CAR-T Therapy for Solid Tumours

Cell Therapies is pleased to support the launch of the CARTiEr E312 Phase I/Ib clinical…

Ryan HardingJuly 8, 2026

News

Cell Therapies and Skin2Neuron Announce Manufacturing Agreement to Advance First in Human Neurorestorative Cell Therapy

Melbourne, Australia - 15th May 2026 Cell Therapies Pty Ltd (“Cell Therapies”), Australia’s leading contract…

Ryan HardingMay 15, 2026

News

AdAlta and Cell Therapies sign first Work Order to bring BZDS1901 manufacturing to Australia

Melbourne, Australia Cell Therapies has executed its first manufacturing work order with AdAlta for their…

Ryan HardingApril 29, 2026

News

Oribiotech, Cell Therapies and AdAlta join forces to tackle cell therapy manufacturing challenges

Melbourne, Australia and London, United Kingdom Ori Biotech, Cell Therapies and AdAlta are joining forces…

Ryan HardingApril 21, 2026

News

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial

Melbourne, Australia The first clinical dose of PMCC-COE19, developed by Peter Mac and manufactured by…

Ryan HardingFebruary 20, 2026

News

Arovella IND Acceptance for iNKT Cell Therapy Platform

Melbourne, Australia Our client Arovella Therapeutics Ltd (ASX: ALA) recently announced that the U.S. Food…

Ryan HardingFebruary 18, 2026

News

ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies

Cell Therapies CEO Bev Menner and ACTRIS Executive Director, A/Prof Aloysius Ho, at Cell Therapies'…

Ryan HardingFebruary 11, 2026

News

Cell Therapies and ENCell Forge Strategic APAC Partnership to Advance Cell and Gene Therapy Manufacturing

Cell Therapies CEO Bev Menner and ENCell Director, CDMO Business Development Gonson Yeom at Cell…

Ryan HardingDecember 5, 2025

News

A-SEEDS and Cell Therapies Announce Manufacturing Partnership to Advance Clinical Trials of Novel CAR-T Cell Therapy

Nagano, Japan / Melbourne, Australia– November 19, 2025 A-SEEDS Co., Ltd., a clinical-stage biotechnology company…

Josh DowningNovember 19, 2025

News

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

October 1, 2025 — Cell Therapies Pty Ltd. (“Cell Therapies”) and Teijin Limited announced today…

Josh DowningSeptember 30, 2025

News

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

Cell Therapies Pty Ltd (Cell Therapies) and Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) have…

Cell TherapiesJuly 16, 2025

News

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC

Cell Therapies and Xellera Therapeutics Enter into a Strategic Partnership to Fast-Track Access to Cell…

Josh DowningApril 1, 2025

Filter

Cell Therapies Supports Commencement of Australian Phase I/Ib Clinical Trial of A-SEEDS’ ACS2015 CAR-T Therapy for Solid Tumours

Translating innovative cell therapies: What is GMP?

Cell Therapies and Skin2Neuron Announce Manufacturing Agreement to Advance First in Human Neurorestorative Cell Therapy

News

Cell Therapies Supports Commencement of Australian Phase I/Ib Clinical Trial of A-SEEDS’ ACS2015 CAR-T Therapy for Solid Tumours

Cell Therapies and Skin2Neuron Announce Manufacturing Agreement to Advance First in Human Neurorestorative Cell Therapy

AdAlta and Cell Therapies sign first Work Order to bring BZDS1901 manufacturing to Australia

Oribiotech, Cell Therapies and AdAlta join forces to tackle cell therapy manufacturing challenges

First patient treated in PLATYPS ‘in-house’ CAR T-cell therapy trial

Arovella IND Acceptance for iNKT Cell Therapy Platform

ACTRIS Signs MoU with Cell Therapies Pty Ltd to Advance CDMO Capabilities for Cell and Gene Therapies

Cell Therapies and ENCell Forge Strategic APAC Partnership to Advance Cell and Gene Therapy Manufacturing

A-SEEDS and Cell Therapies Announce Manufacturing Partnership to Advance Clinical Trials of Novel CAR-T Cell Therapy

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC

Unrivalled experience and service from a global leader in cell and gene therapy manufacturing

Services

Helpful Links

Corporate